Justin Rebo - BioAge Labs, Senior Biology
| BIOA Stock | 18.80 0.49 2.54% |
Executive
Justin Rebo is Senior Biology of BioAge Labs,
| Address | 1445A South 50th Street, Richmond, CA, United States, 94804 |
| Phone | 510 806 1445 |
| Web | https://bioagelabs.com |
Similar Executives
| Found 14 records | EXECUTIVE Age | ||
| Dione Sturgeon | Valvoline | 46 | |
| Yang Li | Tianjin Capital Environmental | 54 | |
| George JD | Asbury Automotive Group | 56 | |
| Jian Zhang | Tianjin Capital Environmental | 65 | |
| John Dalsvag | KNOT Offshore Partners | N/A | |
| Michelle SPHR | Olympic Steel | N/A | |
| Bo Niu | Tianjin Capital Environmental | 46 | |
| Francis Ruane | Olympic Steel | N/A | |
| Christopher Mottet | Valvoline | N/A | |
| Cassandra Powers | Olympic Steel | N/A | |
| Jordan Denny | Valvoline | N/A | |
| Yi Zhao | Tianjin Capital Environmental | 52 | |
| Richard CPA | Olympic Steel | 55 | |
| BRAD PATRICK | Valvoline | 54 | |
BioAge Labs, Leadership Team
Elected by the shareholders, the BioAge Labs,'s board of directors comprises two types of representatives: BioAge Labs, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioAge. The board's role is to monitor BioAge Labs,'s management team and ensure that shareholders' interests are well served. BioAge Labs,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioAge Labs,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Justin Rebo, Senior Biology | ||
| Rusty Montgomery, Senior Research | ||
| Paul MD, Chief Research | ||
| Peng MBA, Chief Aging | ||
| Kristen Fortney, CEO, CoFounder | ||
| Eric MD, COO CoFounder | ||
| MBA MBA, Chief Aging | ||
| Julie Gammelgard, Senior People | ||
| BJ Sullivan, Chief Officer | ||
| Ralph Scarborough, Vice Accounting | ||
| CarrieLynn Furr, Senior Affairs |
BioAge Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioAge Labs, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 539.05 M | ||||
| Shares Outstanding | 34.17 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 32.64 % | ||||
| Number Of Shares Shorted | 2.37 M | ||||
| Price To Earning | (0.84) X | ||||
| EBITDA | (45.81 M) | ||||
| Net Income | (63.85 M) | ||||
| Cash And Equivalents | 4.63 M | ||||
| Cash Per Share | 0.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioAge Labs, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs, Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.40) |
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.